Collaborations

Cardiovascular safety study, other contracts total $8.1M

Published in Vaccine Weekly, January 14th, 2004

Covalent Group, Inc., (CVGR) announced the awarding of multiple studies and contracts with an aggregate value of $8.1 million.

Among the new business awards is a consulting and operational support contract with a European pharmaceutical company for a specialized cardiovascular safety study. The emphasis will be on the QT interval effects of a non-cardiac drug as measured on the electrocardiogram in human subjects. The services to be provided for the study will include investigator site selection and management, oversight of subject recruitment, field monitoring, project management and operations, regulatory operations, and medical monitoring.

The...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2004-01-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry